



## PRODUCT RECALL ALERT

DRAP ALERT NO. N° I/S/05-24-21

### ZAFTOLIN SOLUTION FOR RESPIRATOR BATCH NO. 104

(MANUFACTURED BY MS. ZAFSA PHARMACEUTICAL LABORATORIES (PVT.) LIMITED, KARACHI.)

**Date:** 15<sup>th</sup> May 2024.

#### Target Audience:

- National Regulatory Field Force.
- Pharmacists and Chemists at Distribution, Pharmacies and Medical Stores
- Healthcare Professionals- Physicians, Pharmacists, and Nurses at hospital and clinics etc.

#### Alert Summary:

Provincial Drug Inspector, Karachi took the sample of Zaftolin Respiratory Solution for respirator. Federal Government Analyst, CDL Karachi has declared the Batch No. 104 of the product as of **substandard** quality. Details of the product are given as under:

Details of the affected product is as under:

Product Name	Composition	Batch Details	Manufactured by	Remarks
Zaftolin Respiratory solution  Reg No. 039618	Salbutamol	<b>Batch No. 104</b> Mfg. Date: 06-23 Exp. date: 06-26	M/s. Zafa Pharmaceutical Laboratories Private Limited Karachi.	pH test result not complied with the acceptance criteria.

#### Risk Assessment: -

The impact of use of substandard Zaftolin solution for respirator on the basis of pH may cause sub optimal effect.

#### Action Initiated: -

The manufacturer has been directed to immediately recall the defected batch of product from the market. All pharmacists and chemist working at distributions and pharmacies should **immediately check** their stocks and stop supplying this batch of product. The remaining stock should be quarantined and returned to the supplier/ company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) should also increase surveillance in the market to ensure the effective recall of defective products(s).





-Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the [online form](#), or through phone at +92 51 910 73 17, or by Email at [gsms@dra.gov.pk](mailto:gsms@dra.gov.pk).

### **Advice for Healthcare Professionals: -**

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this affected batch of products.

Adverse reactions or quality problems experienced with the use of this product may be reported to the National Pharmacovigilance Centre (NPC), DRAP using the Adverse Event Reporting Form or online through this [link](#). Further information on reporting problems to DRAP is available on this [link](#).

### **Advice for Consumers / General public: -**

Consumers should stop using this product bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product, and report the incident to the Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.

**All therapeutic goods must be obtained from the licensed pharmacies, and other authorized retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professional in case of any doubt.**



## **Drug Regulatory Authority of Pakistan**

محفوظ، مونثر اور معیاری اشیائے علاج

